

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



愛帝宮母嬰健康股份有限公司
AIDIGONG MATERNAL & CHILD HEALTH LIMITED

(Incorporated in Bermuda with limited liability)

(Stock code: 286)

**(1) QUARTERLY UPDATE ON RESUMPTION PROGRESS;
(2) LITIGATION UPDATES; AND
(3) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09, 13.24A and 13.49(6) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcement of the Company dated 17 January, 5, 13, 18 March, 2, 30 April, 27 June, 20 August, 2 October, 20 November 2025 and 26 January 2026, (collectively, the “**Announcements**”) in relation to, among others, (i) the guidance for the resumption of trading in the Shares set by the Stock Exchange (the “**Resumption Guidance**”); (ii) quarterly updates on the resumption of trading of the shares of the Company; and (iii) the legal proceedings in relation to, among others, the alleged debt due to Shenzhen Aidigong and Ms. Zhu Yufei’s disagreement with Guangdong Wanja regarding the exercise of shareholders rights in Shenzhen Aidigong. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as those defined in the Announcements.

QUARTERLY UPDATE ON RESUMPTION PROGRESS

Business operations

The Group has continued business operations notwithstanding the suspension of trading in the Shares on the Stock Exchange.

Update on the 2024 Annual Results and annual report

The Company is still in the progress of obtaining the necessary financial information on Shenzhen Aidigong and its subsidiaries for the Auditors to conduct the annual audit and prepare the 2024 Annual Results. The expected dates of the publication of the 2024 Annual Results and the annual report for the year ended 31 December 2024 will need to be further agreed with the Auditors, and a separate announcement will be made by the Company as and when appropriate.

Update on resumption progress

The Company remains committed to working towards the resumption of trading in the Shares. As disclosed in the Announcements, the Company encountered difficulties in obtaining relevant documents relating to Shenzhen Aidigong, which have delayed finalizing the scope of the independent forensic investigation into the Matters and the independent internal control review. Meanwhile, the Company continues to engage in discussions with its professional advisers to explore opportunities and formulate a comprehensive and viable resumption proposal to address the matters set out in the Resumption Guidance.

The Company is also reviewing the composition of the Board and will take appropriate steps to fulfill the requirements under Rules 3.10(1), 3.10A, 3.21 and 13.92(2) of the Listing Rules.

The Company has been working, and will continue to work closely with all relevant parties towards the resumption of trading in its shares and will keep shareholders and potential investors informed of progress on fulfilling the Resumption Guidance.

LITIGATION UPDATES

Updates on Arbitration, Litigation, Shenzhen Aidigong Arbitration, Withdrawal of Litigation and Shenzhen Aidigong Litigation

On 4 February 2026, Guangdong Wanjia received a court summons issued by the Shenzhen Futian People's Court, pursuant to which the lawsuit concerning the validity of the Resolution and the Change of Legal Representative is scheduled to be heard in court on 23 March 2026.

The Company is currently seeking legal advice in respect of the claims under the lawsuit above. As the outcome of the lawsuit is uncertain, the Group will make further announcements as and when appropriate in compliance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
Aidigong Maternal & Child Health Limited
Huang Wenhua
Chairman and Executive Director

Hong Kong, 20 February 2026

As at the date of this announcement, the Board comprises Mr. Huang Wenhua and Mr. Li Runping as executive Directors; and Mr. Ma Siu Kit and Mr. Wang Bin as independent non-executive Directors.